Capsule Summary Slidesets

Share

Program Content

Activities

  • MEDALIST
    Phase III MEDALIST: Erythroid Maturation Agent Luspatercept in Very Low– to Intermediate-Risk Myelodysplastic Syndrome With Ring Sideroblasts
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2018

    Expires: December 16, 2019

  • Deferasirox for Iron Chelation
    Phase II TELESTO: Deferasirox vs Placebo in Patients With Low-/Intermediate-Risk Myelodysplastic Syndromes and Iron Overload
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 05, 2018

    Expires: December 04, 2019

  • Ruxolitinib + Thalidomide in MF
    Phase II Trial of Ruxolitinib + Thalidomide in Patients With Myelofibrosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2018

    Expires: December 10, 2019

  • Checkpoint Inhibitors in MDS
    Phase II Trial: Nivolumab or Ipilimumab With or Without Azacitidine in Myelodysplastic Syndromes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2018

    Expires: December 11, 2019

  • Ruxolitinib in aGVHD
    Phase II REACH1: Ruxolitinib + Corticosteroids in Steroid-Refractory Acute Graft-vs-Host Disease
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2018

    Expires: December 11, 2019

  • HAVEN 2: Emicizumab
    Primary Analysis of Phase III HAVEN 2: Emicizumab Prophylaxis in Pediatric Hemophilia A With Factor VIII Inhibitors
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2018

    Expires: December 06, 2019

  • MYF2001: Imetelstat in MF
    MYF2001: Phase II Trial of Imetelstat in Patients With Myelofibrosis Who are Refractory to or Relapsed on JAK Inhibition
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2018

    Expires: December 05, 2019

  • Frontline Eltrombopag in ITP
    Frontline Eltrombopag + Pulsed Dexamethasone in ITP: A Pilot Study
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 05, 2018

    Expires: December 04, 2019

  • Defibrotide for VOD/SOS
    Impact of Defibrotide Initiation Timing on Survival in Adults With VOD/SOS Following HSCT: A Pooled Analysis of CUP and T-IND Cohorts
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2018

    Expires: December 13, 2019

  • Avatrombopag in cITP
    Avatrombopag in Chronic ITP: Assessment of Gastric Toxicity in 2 Phase III Studies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2018

    Expires: December 05, 2019

  • CASSINI: Rivaroxaban
    Phase III CASSINI: Rivaroxaban vs Placebo as VTE Prophylaxis in Ambulatory Patients With Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2018

    Expires: December 10, 2019

  • Luspatercept in β-Thalassemia
    BELIEVE: Phase III Study of Luspatercept vs Placebo in Beta-Thalassemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology